Suppr超能文献

大鼠质量效应的实验评估:对小动物PET成像的启示

Experiment assessment of mass effects in the rat: implications for small animal PET imaging.

作者信息

Jagoda E M, Vaquero J J, Seidel J, Green M V, Eckelman W C

机构信息

PET Dept., Warren Grant Magnuson Clinical Center, Bethesda, MD 20892-1180, USA.

出版信息

Nucl Med Biol. 2004 Aug;31(6):771-9. doi: 10.1016/j.nucmedbio.2004.04.003.

Abstract

In vivo imaging using positron emission tomography (PET) is important in the development of new radiopharmaceuticals in rodent animal models for use as biochemical probes, diagnostic agents, or in drug development. We have shown mathematically that, if small animal imaging studies in rodents are to have the same "quality" as human PET studies, the same number of coincidence events must be detected from a typical rodent imaging "voxel" as from the human imaging voxel. To achieve this using the same specific activity preparation, we show that roughly the same total amount of radiopharmaceutical must be given to a rodent as to a human subject. At high specific activities, the mass associated with human doses, when administered to a rodent, may not decrease the uptake of radioactivity at non saturable sites or sites where an enzyme has a high capacity for a substrate. However, in the case of binding sites of low density such as receptors, the increased mass injected could saturate the receptor and lead to physiologic effects and non-linear kinetics. Because of the importance of the mass injected for small animal PET imaging, we experimentally compared high and low mass preparations using ex vivo biodistribution and phosphorimaging of three compounds: 2-fluoro-2-deoxyglucose (FDG), 6-fluoro-L-metatyrosine (FMT) and one receptor-directed compound, the serotonin 5HT1A receptor ligand, trans-4-fluoro-N-[2-[4-(2-methoxylphenyl) piperazino]ethyl]-N-(2-pyridyl) cyclohexane- carboxamide (FCWAY). Changes in the mass injected per rat did not affect the distribution of FDG, FMT, and FCWAY in the range of 0.6-1.9 nmol per rat. Changes in the target to nontarget ratio were observed for injected masses of FCWAY in the range of approximately 5-50 nmol per rat. If the specific activity of such compounds and/or the sensitivity of small animal scanners are not increased relative to human studies, small animal PET imaging will not correctly portray the "true" tracer distribution. These difficulties will only be exacerbated in animals smaller than the rat, e.g., mice.

摘要

在啮齿动物模型中,使用正电子发射断层扫描(PET)进行体内成像对于开发用作生化探针、诊断剂或用于药物研发的新型放射性药物至关重要。我们已通过数学证明,如果啮齿动物的小动物成像研究要具有与人类PET研究相同的“质量”,那么从典型的啮齿动物成像“体素”中检测到的符合事件数量必须与从人类成像体素中检测到的相同。为了使用相同的比活制剂实现这一点,我们表明给予啮齿动物的放射性药物总量必须与给予人类受试者的大致相同。在高比活时,给予啮齿动物的与人类剂量相关的质量,可能不会降低非饱和位点或酶对底物具有高容量位点处的放射性摄取。然而,在诸如受体等低密度结合位点的情况下,注入质量的增加可能会使受体饱和并导致生理效应和非线性动力学。由于注入质量对小动物PET成像很重要,我们使用三种化合物的离体生物分布和磷光成像实验性地比较了高剂量和低剂量制剂:2-氟-2-脱氧葡萄糖(FDG)、6-氟-L-间酪氨酸(FMT)和一种受体导向化合物,血清素5HT1A受体配体,反式-4-氟-N-[2-[4-(2-甲氧基苯基)哌嗪基]乙基]-N-(2-吡啶基)环己烷-羧酰胺(FCWAY)。每只大鼠注入质量的变化在每只大鼠注射0.6 - 1.9 nmol的范围内不影响FDG、FMT和FCWAY的分布。对于每只大鼠注射质量在约5 - 50 nmol范围内的FCWAY,观察到靶与非靶比值的变化。如果相对于人类研究,此类化合物的比活和/或小动物扫描仪的灵敏度没有提高,小动物PET成像将无法正确描绘“真实”的示踪剂分布。这些困难在比大鼠更小的动物(如小鼠)中只会更加严重。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验